Core Insights - INmune Bio Inc. has submitted a pre-submission package for CORDStrom™ to the UK Medicines and Healthcare Products Regulatory Agency (MHRA), aiming to expedite the approval process for a potential systemic therapy for recessive dystrophic epidermolysis bullosa (RDEB) [1][3] - CORDStrom is being developed as a disease-modifying treatment for RDEB, a rare genetic disorder affecting approximately 1 in 1 million births globally, with no approved systemic therapies currently available [2][5] - The company has completed three commercial pilot-scale manufacturing runs, confirming readiness for commercial supply and plans to file a full Marketing Authorization Application (MAA) with MHRA by mid-summer 2026 [3][4] Regulatory and Legislative Context - CORDStrom has received Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) designation in the U.S., which are significant due to the recent reauthorization of the FDA's Rare Pediatric Disease Priority Review Voucher (PRV) program through September 30, 2029 [4][5] - The reauthorization of the PRV program strengthens incentives for developing therapies for rare pediatric diseases, potentially benefiting INmune Bio as it prepares for a Biologics License Application (BLA) submission later this year [5] Product and Technology Overview - CORDStrom™ is a patent-pending cell medicine utilizing pooled human umbilical cord-derived mesenchymal stromal cells (hucMSCs), designed for injection or infusion to treat complex inflammatory and autoimmune diseases [7] - The platform allows for the creation of indication-specific products that can be optimized for various therapeutic characteristics, addressing severe unmet needs in RDEB patients [7][8]

Core Viewpoint - Fortress Biotech and its subsidiary Cyprium Therapeutics received a Complete Response Letter from the FDA regarding the New Drug Application for CUTX-101, intended for treating Menkes disease in pediatric patients [1][3]. Group 1: Company Developments - In December 2023, Sentynl Therapeutics assumed full responsibility for the development and commercialization of CUTX-101 from Cyprium [2]. - Sentynl expects to address the FDA's concerns and pursue resubmission of the CUTX-101 NDA promptly [2][3]. - The CRL highlighted cGMP deficiencies at the manufacturing facility, but did not raise concerns regarding the efficacy and safety data of CUTX-101 [3]. Group 2: Financial and Regulatory Aspects - Sentynl will transfer a Rare Pediatric Disease Priority Review Voucher to Cyprium upon approval and Cyprium is eligible for royalties on net sales of CUTX-101, along with up to $129 million in development and sales milestones [4]. - The CUTX-101 NDA was initially granted Priority Review by the FDA, supported by positive clinical efficacy results showing significant improvement in overall survival for Menkes disease patients receiving early treatment [5]. Group 3: Disease Background - Menkes disease is a rare X-linked recessive pediatric condition caused by mutations in the copper transporter ATP7A, with a birth prevalence estimated between 1 in 34,810 and 1 in 8,664 live male births [6]. - The disease is characterized by severe neurological symptoms and high mortality rates in untreated cases, with many patients not surviving past the age of 2-3 years [6]. Group 4: Company Overview - Cyprium Therapeutics focuses on developing therapies for Menkes disease and related disorders, having entered into a Cooperative Research and Development Agreement with the NIH to advance CUTX-101 [7]. - Fortress Biotech is an innovative biopharmaceutical company with a diverse portfolio, including eight marketed products and multiple development programs across various therapeutic areas [8][9].